US-Based Gilead To Acquire CymaBay Therapeutics For $4.3B To Expand Liver Portfolio

This post was originally published on Forbes Middle East

US-based pharmaceutical company Gilead Sciences announced a definitive agreement on Monday to acquire CymaBay Therapeutics, primarily for its chronic liver disease drug seladelpar, for a total equity value of $4.3 billion.